Male infertility affects roughly one in six couples worldwide, yet evidence-based treatments for the most severe forms — where sperm production itself is compromised — remain frustratingly sparse. A rigorous randomized trial now offers a credible therapeutic signal for letrozole, an aromatase inhibitor long used in breast oncology, repositioned here for men whose fertility specialists have had little to offer beyond assisted reproduction.
This multicenter Chinese trial enrolled 296 men (mean age 30.2 years) diagnosed with spermatogenic failure — encompassing nonobstructive azoospermia, cryptozoospermia, and severe oligozoospermia, with 73.6% falling into the hardest-to-treat azoospermia category. Participants were randomized to either letrozole 2.5 mg daily plus vitamins C and E, or vitamins C and E alone, for three months. The primary endpoint was the rate of upgrade across WHO Sperm Concentration Categories. Secondary endpoints included total motile sperm count classifications, raw semen parameters, and reproductive hormone profiles. Roughly 83% of participants completed the trial, lending reasonable statistical integrity to the findings.
Aromatase inhibitors work by blocking the peripheral conversion of testosterone to estradiol, thereby shifting the testosterone-to-estrogen ratio and theoretically amplifying gonadotropin signaling to Sertoli and Leydig cells. The pharmacological rationale is sound, and small observational studies have hinted at benefit for years — but this trial is among the largest and most rigorously designed to date. It is worth noting the open-label design (assessors were blinded, not participants) and the exclusively Chinese cohort, which may limit generalizability to populations with different baseline hormone profiles or etiological distributions of SPGF. Three months is also a single spermatogenic cycle, and whether gains persist or translate into live birth rates — the outcome patients actually care about — remains unknown. For now, this represents a meaningful incremental advance, likely sufficient to shift clinical conversation but not yet practice guidelines.